MIST: Rapid drug launch, strong provider uptake, and AFib trial progress drive growth outlook

FDA approval and rapid launch of a new drug have led to positive provider feedback and growing patient momentum. Electrophysiologists are adopting quickly, and a phase III AFib trial is underway, leveraging prior experience. Cash runway extends into the second half of next year.Based on Milestone P…